Novartis has published its 2015 Corporate Responsibility (CR) Performance Report.
The report is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level, making it the first comprehensive level-report in the healthcare industry. In addition, the publication of the CR report now coincides with the Novartis Annual Report, providing a more integrated view on the company’s performance.
The report is based on the results of the CR materiality analysis review conducted in 2015, which reconfirmed that access, ethics, and research and development are our most important issues. In addition, it offers insights into how Novartis manages CR, including the company’s access framework, showing the variety of approaches and models used to expand access to healthcare globally.
Novartis 2015 CR highlights:
- Launched Novartis Access, a portfolio of 15 medicines to treat the main noncommunicable diseases in lower-income countries at a cost of USD 1 per treatment per month.
- Provided medicine to 66 million patients through access programmes.
- Reached 7,6 million people through social business initiatives in India, Kenya, Vietnam and Indonesia.
- Launched a new Group-wide programmes to ensure our ethical standards are firmly embedded in our business practices.
- Trained more than 110, 000 Novartis associates on the company’s Code of Conduct.
- Set a new 2030 company vision on environmental sustainability with a 30% reduction target in global greenhouse gas emissions by 2020 vs. 2010.
- Recognised in major CR-related indices, such as Dow Jones Sustainability Index and FTSE4Good, as well as, most recently, in the Global 100 Most Sustainable Corporations in the World Index by Corporate Knights.